Journal Logo

Most Popular Articles

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer

Koh, Yoko; Kawashima, Atsunari; Ujike, Takeshi; More

Anti-Cancer Drugs. 31(10):1099-1102, November 2020.

Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

Gürler, Fatih; İlhan, Ayşegül; Güven, Deniz Can; More

Anti-Cancer Drugs. 33(1):e477-e485, January 2022.

The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis

Zhang, Linhui; Song, Guohong; Shao, Bin; More

Anti-Cancer Drugs. 33(1):e635-e643, January 2022.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

Leonard, Shannon C.; Lee, Helen; Gaddy, Daniel F.; More

Anti-Cancer Drugs. 28(10):1086-1096, November 2017.

Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non–small-cell lung cancer: a case report

Liu, Yunpeng; Gao, Zhiru; Zhang, Chengbin; More

Anti-Cancer Drugs. 33(1):e784-e788, January 2022.

Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine

Sun, Jie; Ning, Shangyong; Feng, Ru; More

Anti-Cancer Drugs. 33(1):e813-e817, January 2022.

Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study

Kurosaki, Takashi; Mitani, Seiichiro; Tanaka, Kaoru; More

Anti-Cancer Drugs. 32(1):95-101, January 2021.

The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes

Stathopoulos, George P.; Malamos, Nikolaos A.; Markopoulos, Christos; More

Anti-Cancer Drugs. 25(8):950-957, September 2014.

Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis

Kanbayashi, Yuko; Hosokawa, Toyoshi; Okamoto, Kousuke; More

Anti-Cancer Drugs. 21(9):877-881, October 2010.

Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab

Marushima, Hideki; Kimura, Hiroyuki; Miyazawa, Tomoyuki; More

Anti-Cancer Drugs. 31(2):177-182, February 2020.

Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

Sanfilippo, Roberta; Dileo, Palma; Blay, Jean-Yves; More

Anti-Cancer Drugs. 26(6):678-681, July 2015.

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Bernier, Cynthia; Soliman, Ahmed; Gravel, Michel; More

Anti-Cancer Drugs. 29(8):774-785, September 2018.

Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer

Kim, Hyo Song; Yi, Seong Yoon; Jun, Hyun Jung; More

Anti-Cancer Drugs. 21(1):107-112, January 2010.